| [1] |
王波，余楠生. 膝骨关节炎阶梯治疗专家共识(2018年版)[J/CD]. 中华关节外科杂志(电子版), 2019, 13(1): 124－130.
|
| [2] |
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis[J]. Lancet, 2019, 393(10182): 1745－1759.
|
| [3] |
Francisco V, Pérez T, Pino J, et al. Biomechanics, obesity, and osteoarthritis. The role of adipokines: when the levee breaks[J]. J Orthop Res, 2018, 36(2): 594－604.
|
| [4] |
Ratneswaran A, Sun MM, Dupuis H, et al. Nuclear receptors regulate lipid metabolism and oxidative stress markers in chondrocytes[J]. J Mol Med (Berl), 2017, 95(4): 431－444.
|
| [5] |
Cheng HS, Tan WR, Low ZS, et al. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence[J/OL]. Int J Mol Sci, 2019, 20(20): 5055. DOI: 10.3390/ijms20205055.
|
| [6] |
杨蓉蓉，张莉，张向颖，等. 过氧化物酶体增殖物激活受体α(PPARα)对脂多糖刺激巨噬细胞引发炎症反应的影响[J]. 中华微生物学和免疫学杂志，2015, 35(6): 431－435.
|
| [7] |
Christofides A, Konstantinidou E, Jani C, et al. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses[J/OL]. Metabolism, 2021, 114: 154338. DOI: 10.1016/j.metabol.2020.154338.
|
| [8] |
Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications[J]. Eur J Med Chem, 2019, 166: 502－513.
|
| [9] |
Bougarne N, Paumelle R, Caron S, et al. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB[J]. Proc Natl Acad Sci U S A, 2009, 106(18): 7397－7402.
|
| [10] |
Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets[J]. Cell Biochem Biophys, 2000, 32 Spring: 187－204.
|
| [11] |
Berger J, Moller DE. The mechanisms of action of PPARs[J]. Annu Rev Med, 2002, 53: 409－435.
|
| [12] |
Zhang J, Liu X, Xie XB, et al. Multitargeted bioactive ligands for PPARs discovered in the last decade[J]. Chem Biol Drug Des, 2016, 88(5): 635－663.
|
| [13] |
Amber-Vitos O, Chaturvedi N, Nachliel E, et al. The effect of regulating molecules on the structure of the PPAR-RXR complex[J]. Biochim Biophys Acta, 2016, 1861(11): 1852－1863.
|
| [14] |
Ammazzalorso A, de Filippis B, Giampietro L, et al. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview[J]. Chem Med Chem, 2013, 8(10): 1609－1616.
|
| [15] |
Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD[J]. Nat Rev Endocrinol, 2017, 13(1): 36－49.
|
| [16] |
韩斌，施桥发，王美珍，等. 抵抗素通过PPARγ/NF-κB信号通路调控脂多糖诱导的炎症反应[C]. //第十三届全国免疫学学术大会会议论文，上海，2018.
|
| [17] |
Huang H, Wang ZJ, Zhang HB, et al. The function of PPARγ/AMPK/SIRT-1 pathway in inflammatory response of human articular chondrocytes stimulated by advanced glycation end products[J]. Biol Pharm Bull, 2019, 42(8): 1303－1309.
|
| [18] |
Alford KA, Glennie S, Turrell BR, et al. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling[J]. J Biol Chem, 2007, 282(9): 6232－6241.
|
| [19] |
Hou Y, Moreau F, Chadee K. PPARγ is an E3 ligase that induces the degradation of NFκB/p65 [J/OL]. Nat Commun, 2012, 3: 1300. DOI: 10.1038/ncomms2270.
|
| [20] |
Zhao M, Bian YY, Yang LL, et al. HuoXueTongFu formula alleviates intraperitoneal adhesion by regulating macrophage polarization and the SOCS/JAK2/STAT/PPAR- γ signalling pathway[J/OL]. Mediators Inflamm, 2019, 2019: 1769374. DOI: 10.1155/2019/1769374.
|
| [21] |
Gou Q, Gong X, Jin J, et al. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy[J]. Oncotarget, 2017, 8(36): 60704－60709.
|
| [22] |
Zhou D, Ji L, Chen Y. TSPO modulates IL-4-induced microglia/macrophage M2 polarization via PPAR-γ pathway[J]. J Mol Neurosci, 2020, 70(4): 542－549.
|
| [23] |
El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression[J/OL]. Springer Plus, 2016, 5(1): 1508. DOI: 10.1186/s40064-016-3197-y.
|
| [24] |
Moqbel SAA, He Y, Xu L, et al. Rat chondrocyte inflammation and osteoarthritis are ameliorated by madecassoside[J/OL]. Oxid Med Cell Longev, 2020, 2020: 7540197. DOI: 10.1155/2020/7540197.
|
| [25] |
Seidl CI, Murphy CL. Dual and opposing regulation of MMP1 and MMP13 by both arms of miR-675 in human articular chondrocytes[J]. Cell Physiol Biochem, 2019, 53(1): 172－185.
|
| [26] |
Ji B, Ma Y, Wang H, et al. Activation of the P38/CREB/MMP13 axis is associated with osteoarthritis[J]. Drug Des Devel Ther, 2019, 13: 2195－2204.
|
| [27] |
Qiu L, Luo Y, Chen X. Quercetin attenuates mitochondrial dysfunction and biogenesis via upregulated AMPK/SIRT1 signaling pathway in OA rats[J]. Biomed Pharmacother, 2018, 103: 1585－1591.
|
| [28] |
Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, et al. Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage[J]. Osteoarthritis Cartilage, 2011, 19(7): 895－902.
|
| [29] |
Ratneswaran A, LeBlanc EA, Walser E, et al. Peroxisome proliferator-activated receptor δ promotes the progression of posttraumatic osteoarthritis in a mouse model[J]. Arthritis Rheumatol, 2015, 67(2): 454－464.
|
| [30] |
Vasheghani F, Zhang Y, Li YH, et al. PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage[J]. Ann Rheum Dis, 2015, 74(3): 569－578.
|
| [31] |
Wang Y, Zhao X, Lotz M, et al. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α[J]. Arthritis Rheumatol, 2015, 67(8): 2141－2153.
|
| [32] |
Kim DH, Kim DH, Heck BE, et al. PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-Γ[J]. Regen Ther, 2020, 15: 103－111.
|
| [33] |
Zhu X, Chen F, Lu K, et al. PPARγ preservation via promoter demethylation alleviates osteoarthritis in mice[J]. Ann Rheum Dis, 2019, 78(10): 1420－1429.
|
| [34] |
Kang S, Zhang J, Yuan Y. Abietic acid attenuates IL-1β-induced inflammation in human osteoarthritis chondrocytes[J]. Int Immunopharmacol, 2018, 64: 110－115.
|
| [35] |
François M, Richette P, Tsagris L, et al. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes[J]. Arthritis Rheum, 2006, 54(4): 1233－1245.
|